A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

NCT04278924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG: Placebo
DRUG: TAK-079

Sponsor

Takeda